Study of TAK-925 in Participants With Obstructive Sleep Apnea (OSA) Who Are Experiencing Excessive Daytime Sleepiness (EDS) Despite Current or Prior Use of a Primary OSA Therapy
Condition: Obstructive Sleep Apnea Interventions: Drug: TAK-925; Drug: Placebo Sponsor: Millennium Pharmaceuticals, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Obstructive Sleep Apnea | Research | Sleep Apnea | Sleep Disorders | Sleep Medicine | Study